Showing results (71-80 of 415) with videos related to
Sort By:
Pageof 42
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab InvestigatorsAmanda B Spurdle, Sunil R Lakhani, Sue Healey, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 3, 2002
The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 yearsAmanda B Spurdle, John L Hopper, Xiaoqing Chen, et al.American Journal of Human Genetics|September 2, 2020
eQTL Colocalization Analyses Identify NTN4 as a Candidate Breast Cancer Risk GeneJonathan Beesley, Haran Sivakumaran, Mahdi Moradi Marjaneh, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 16, 2004
Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancersAndrew Berchuck, Joellen M Schildkraut, Robert M Wenham, et al.Human Mutation|August 27, 2005
A protein-truncating mutation in CYP17A1 in three sisters with early-onset breast cancerJohn L Hopper, Vanessa M Hayes, Amanda B Spurdle, et al.Breast Cancer Research and Treatment|October 26, 2006
Prediction of BRCA1 and BRCA2 mutation status using post-irradiation assays of lymphoblastoid cell lines is compromised by inter-cell-line phenotypic variabilityPaul K Lovelock, Ee Ming Wong, Carl N Sprung, et al.Human Mutation|October 13, 2011
Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patientsElla R Thompson, Samantha E Boyle, Julie Johnson, et al.Oncotarget|April 26, 2014
Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancerFares Al-Ejeh, Mariska Miranda, Wei Shi, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 9, 2013
Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitorFares Al-Ejeh, Wei Shi, Mariska Miranda, et al.Breast Cancer Research and Treatment|August 26, 2017
Panel sequencing of 264 candidate susceptibility genes and segregation analysis in a cohort of non-BRCA1, non-BRCA2 breast cancer familiesJun Li, Hongyan Li, Igor Makunin, et al.Pageof 42